EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY 4.0

Association between pancreatic enzyme replacement therapy and mortality in pancreatic cancer: a matched case-control study

Ana Dugic, Hannes Hagström, Isabella Palmer, Amar Nouri, Hasti Torabzadeh Tari, Lena Schmaderer, Maria Gustafsson Liljefors, Poya Ghorbani, J-Matthias Löhr, Miroslav Vujasinovic

Pancreatology · 2026-02 · 26 (1) · 130-137

DOI: 10.1016/j.pan.2025.12.008 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Pancreatology, 2026-02. Verfasst von Ana Dugic und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden; Department of Medicine IV, Heidelberg University Hospital, Heidelberg, Ger…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Enzyme Replacement Therapy, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Malnutrition and pancreatic exocrine insufficiency (PEI) are common among patients with pancreatic cancer. Despite the potential of pancreatic enzyme replacement therapy (PERT) to correct PEI, its association with survival remains uncertain. Our study aimed to evaluate the trend in PERT prescription and its potential association with mortality among patients with pancreatic cancer. METHODS: We included patients with pancreatic ductal adenocarcinoma (PDAC) discussed at a tertiary hospital tumor board between 2008-2012 and 2015-2018. Cases (deceased within one year) were matched 1:1 with controls (alive at one year). Patients were classified as PERT users or non-users based on prescriptions after PDAC diagnosis. Conditional logistic regression assessed the association between PERT usage and all-cause mortality at one-year post-diagnosis. RESULTS: A total of 1247 patients were included: 756 (61 %) who died within one year and 491 (39 %) who survived. PERT prescriptions increased over time, particularly in the palliative setting (46 % vs. 75 %, p = 0.001). Matching yielded 487 pairs. In the full population, PERT use was associated with lower one-year mortality (adjusted OR 0.49, 95 %CI = 0.34-0.71). Similar associations were seen among subgroups undergoing surgery (aOR 0.34, 95 %CI = 0.16-0.74) and those receiving best supportive care (aOR 0.12, 95 %CI = 0.03-0.33). In the chemotherapy-only subgroup, the direction of effect suggested a potential risk reduction, but without statistical significance (aOR 0.75, 95 %CI = 0.44-1.24). CONCLUSION: There is an overall decrease in mortality among PERT-users compared to non-users. The results may be overly optimistic due to potential confounding factors related to patient selection, and randomized controlled studies are needed to confirm these effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsEnzyme Replacement TherapyCarcinoma, Pancreatic DuctalHumansMaleFemaleCase-Control StudiesAgedMiddle AgedExocrine Pancreatic InsufficiencyAged, 80 and over

Stichwörter der Autor:innen

Enzyme replacementMortalityPDACPERTPancreatic cancer

Autor:innen und Institutionen

  • Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden; Department of Medicine IV, Heidelberg University Hospital, Heidelberg, Germany. Electronic address: ana.dugic@ki.se.
  • Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden; Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden. Electronic address: hannes.hagstrom@ki.se.
  • Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden. Electronic address: isabella.palmer@regionstockholm.se.
  • Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden.
  • Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden. Electronic address: hasti.torabzadeh.tari@stud.ki.se.
  • Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden. Electronic address: lena.schmaderer@gmx.de.

Zitieren

APA

Dugic, A., Hagström, H., Palmer, I., Nouri, A., Tari, H. T., Schmaderer, L., Liljefors, M. G., Ghorbani, P., Löhr, J. M., & Vujasinovic, M. (2026). Association between pancreatic enzyme replacement therapy and mortality in pancreatic cancer: a matched case-control study. Pancreatology, 26(1), 130-137. https://doi.org/10.1016/j.pan.2025.12.008

Vancouver

Dugic A, Hagström H, Palmer I, Nouri A, Tari HT, Schmaderer L, et al. Association between pancreatic enzyme replacement therapy and mortality in pancreatic cancer: a matched case-control study. Pancreatology. 2026;26(1):130-137. doi:10.1016/j.pan.2025.12.008

BibTeX
@article{Dugic2026,
  author = {Dugic, Ana and Hagström, Hannes and Palmer, Isabella and Nouri, Amar and Tari, Hasti Torabzadeh and Schmaderer, Lena and Liljefors, Maria Gustafsson and Ghorbani, Poya and Löhr, J-Matthias and Vujasinovic, Miroslav},
  title = {Association between pancreatic enzyme replacement therapy and mortality in pancreatic cancer: a matched case-control study},
  journal = {Pancreatology},
  year = {2026},
  volume = {26},
  number = {1},
  pages = {130--137},
  doi = {10.1016/j.pan.2025.12.008}
}
Kostenlos starten →